Abstract: Objective The aim of this study was to analyze the short-term efficacy of glicladine and insulin aspart 50 in the treatment of patients with non-alcoholic fatty liver diseases (NAFLD) and hepatogenic diabetes and to monitor the changes of homeostasis model assessment for insulin resistance (HOMA-IR) and index of β-cell function in homeostasis model assessment (HOMA-β).Methods 98 patients with NAFLD and hepatogenic diabetes were admitted to our hospital between January 2017 and December 2019 were randomly divided into control group (n=49) and observation group (n=49). The patients in the control group were treated with insulin aspart 50, while those in the observation group were treated with glicladine at the basis of insulin aspart 50. The regimen in both groups lasted for 12 weeks. The fasting blood glucose (FBG) , postprandial 2 hour blood glucose (2 h PG) and serum hemoglobin A1c (HbAlc) level were detected, and the HOMA-IR and HOMA-β were calculated. Serum liver function indexes were detected by automatic biochemical analyzer.Results At the end of 12 week treatment, the FPG level in observation group was (6.3±3.9) mmol/l, significantly lower than [ (7.8 ±1.2) mmol/l, P<0.05] in the control, the 2 h PG level was (8.4±2.6) mmol/l, significantly lower than [(11.5±2.8) mmol/l, P<0.05] in the control, and the HbAlc level was (7.1±1.6)%, significantly lower than [(8.3±1.9)%, P<0.05] in the control; the HOMA-IR in the observation group was (1.5±0.2) , significantly lower than [(2.4±03), P<0.05] in the control, while the HOMA-β was (42.9±8.7), significantly higher than [(33.5±7.2), P<0.05] in the control; serum alanine aminotransferase (ALT) level in the observation group was (53.9±13.7) U/L, significantly lower than [(72.2±19.6) U/L, P<0.05] in the control, and serum aspartate aminotransferase (AST) level was (22.1±6.3) U/L, significantly lower than [(46.4±6.9) U/L, P<0.05] in the control; Serum albumin, total bilirubin and glutamyl transpeptidase levels in the two groups were not significantly different before and after treatment (P>0.05).Conclusion The administration of glicladine and insulin aspart 50 in the treatment of patients with NAFLD and hepatogenic diabetes could significantly improve the blood sugar level recovery, which might related to the improvement of islet β cell functions and reduction of HOMA-IR.

Key words: Non-alcoholic fatty liver diseases, Hepatogenic diabetes, Glicladine, Insulin aspart 50, Homeostasis model assessment for insulin resistance, Index of β-cell function in homeostasis model assessment, Therapy